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N-of-1 Trial of a Statin, Placebo, or No Treatment  
to Assess Side Effects
To the Editor: Statins are often discontinued 
because of side effects,1,2 even though some 
blinded trials have not shown an excess of symp-
toms with statins as compared with placebo.3,4 
Patients who had previously discontinued statins 
because of side effects that occurred within 2 
weeks after the initiation of treatment were en-
rolled in a double-blind, three-group, n-of-1 trial 
to test whether symptoms would be induced by 
a statin or placebo. Details of the trial methods 
are provided in Section S2 in the Supplementary 
Appendix (available with the full text of this let-
ter at NEJM.org); the trial protocol and statistical 
analysis plan are also available at NEJM.org.
The patients received four bottles containing 
atorvastatin at a dose of 20 mg, four bottles 
containing placebo, and four empty bottles; each 
bottle was to be used for a 1-month period ac-
cording to a random sequence. The patients used 
a smartphone application to report symptom in-
tensity daily. Symptom scores ranged from 0 (no 
symptoms) to 100 (worst imaginable symptoms). 
If the patients determined that their symptoms 
were unacceptably severe, they could discontinue 
the tablets for that month.
The primary end point was symptom inten-
sity as assessed with the use of the nocebo ratio 
(i.e., the ratio of symptom intensity induced by 
taking placebo to the symptom intensity induced 
by taking a statin). This ratio was calculated as 
the symptom intensity with placebo minus the 
symptom intensity with neither statin nor pla-
cebo, divided by the symptom intensity with a 
statin minus the symptom intensity with neither 
statin nor placebo.
From June 2016 through March 2019, a total 
of 60 patients underwent randomization. The 
screening data, the baseline characteristics of the 
patients, and a diagram showing screening, ran-
domization, intervention, and follow-up are pro-
vided in Sections S1 through S3 in the Supplemen-
tary Appendix. A total of 49 patients completed 
all 12 months of the trial.
The original primary end-point analysis showed 
a nocebo ratio of 2.2 (95% confidence interval [CI], 
−62.3 to 66.7). This value was high and had a 
wide confidence interval because in some of the 
patients the value of the symptom intensity with 
statins minus the symptom intensity with nei-
ther statin nor placebo was unexpectedly small 
or negative. An independent statistician therefore 
recommended a different analysis (see Section S2 
in the Supplementary Appendix) in which indi-
vidual patient data were pooled before calcula-
tion of the ratio. This analysis showed a nocebo 
ratio of 0.90. Among all 60 patients, the mean 
symptom intensity was 8.0 during no-tablet 
months (95% CI, 4.7 to 11.3), 15.4 during pla-
cebo months (95% CI, 12.1 to 18.7; P<0.001 for 
the comparison with no-tablet months), and 
16.3 during statin months (95% CI, 13.0 to 19.6; 
P<0.001 for the comparison with no-tablet months 
and P = 0.39 for the comparison with placebo 
months) (Fig. 1). Adverse events are listed in Sec-
tion S4 in the Supplementary Appendix.
Six months after completion of the trial, 30 
of the patients (50%) had successfully restarted 
statins, 4 planned to do so, and 1 could not be 
contacted. The remaining 25 patients were not 
receiving statins and were not planning to restart 
statins. The reasons given by these 25 patients for 
not planning to restart statins are listed in Sec-
tion S3 in the Supplementary Appendix.
In patients who had discontinued statin thera-
py because of side effects, 90% of the symptom 
burden elicited by a statin challenge was also 
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elicited by placebo. Half the trial patients were 
able to successfully restart statins.
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Figure 1. Symptom Scores for All the Trial Patients.
Shown are mean symptom scores for the 49 patients who completed all 12 months of the trial (left) and those for the 11 patients who 
did not complete all 12 months (right). Each circle represents a single month for each patient. Symptoms were reported daily, and the 
mean symptom score was calculated for the month regardless of whether the patient discontinued the assigned bottle at any time dur-
ing that month.
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